New drug offers better pain relief with fewer side effects
We noticed that Grünenthal, a German pharmaceutical company, has submitted a Marketing Authorisation Application for tapentadol tablets to several European authorities. Grünenthal is seeking an indication for the treatment of severe acuteHas a sudden onset. and severe chronicA disease of long duration generally involving slow changes. pain requiring centrally acting analgesicsAnother term for painkillers. therapy in adults. If approved Tapentadol will be the first of a new generation of centrally-acting analgesics. In the United States, the IR formulation of tapentadol has already been approved by the Food and Drug Administration (FDA) for the relief of moderate to severe acute pain in adult patients.
“Many patients suffer from pain because available treatment options do not provide sufficient pain relief, or have other limitations such as gastro-intestinalrelating to the intestines, the digestive tract between the stomach and the anus side effects that may trigger patients to discontinue treatment”, says Wolfgang Becker, Corporate Executive Board Member. “We are convinced that tapentadol has the potential to contribute to overcoming these unmet medical needs and help to improve pain management.”
Consultant Interventional Spine and Pain Physician Nigel Kellow says:
This is potentially exciting. We have always had particular difficulties with the side effects of strong analgesics. The most common side effects with morphine and other opioids are nausea, vomitingExpusion of the contents of the stomach through the mouth., constipationa common condition where stools are not passed as frequently as normal, and drowsiness. Any drug that can offer similar quality pain relief with fewer side effects will be welcomed by all doctors who look after patients in pain.




